Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menstrual Disorder Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users

NCT03335163
View directory record Official record
Conditions
Migraine, Migraine;Menstrual, Contraception
Interventions
Topiramate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)

NCT00965562
View directory record Official record
Conditions
Premenstrual Syndrome
Interventions
Fluoxetine, Calcium, Placebo
Drug
Lead sponsor
Donaghue Medical Research Foundation
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 24, 2026, 1:03 AM EDT
Recruiting Not applicable Interventional

An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms

NCT07078682
View directory record Official record
Conditions
Uterine Fibroids, Leiomyoma, Menstrual Pain
Interventions
Elix Daily Harmony
Dietary Supplement
Lead sponsor
Zenchi, Inc.
Industry
Eligibility
20 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Leptin for the Treatment of Hypothalamic Amenorrhea

NCT00130117
View directory record Official record
Conditions
Amenorrhea
Interventions
r-metHuLeptin, Oral Contraceptive Pills (OCPs), Placebo
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03070951
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Chino, California • Huntington Park, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 24, 2026, 1:03 AM EDT
Completed No phase listed Observational

Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients

NCT00001837
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Phase 3 Interventional

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03204318
View directory record Official record
Conditions
Endometriosis Related Pain
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Intense Training on Ovarian Function and Bone Turnover

NCT02224976
View directory record Official record
Conditions
Amenorrhea
Interventions
Intensified Training
Behavioral
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes

NCT02693938
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Follicular Euglycemic clamp, Luteal Euglycemic clamp
Device
Lead sponsor
Yale University
Other
Eligibility
12 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196313
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, Placebo tablet
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
Up to 17 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
13
States / cities
Denver, Colorado • Decatur, Georgia • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome

NCT01788215
View directory record Official record
Conditions
Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
Interventions
doxycycline, Sugar Pill
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Phase 4 Interventional Results available

Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding

NCT01190150
View directory record Official record
Conditions
Menorrhagia
Interventions
tranexamic acid
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
12 Years to 16 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 24, 2026, 1:03 AM EDT
Not listed Phase 2 Interventional

Pulsatile GnRH in Anovulatory Infertility

NCT00383656
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Amenorrhea, Kallmann's Syndrome
Interventions
GnRH, Pump
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 24, 2026, 1:03 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump

NCT07152730
View directory record Official record
Conditions
Amenorrhea, Fertility, Infertility
Interventions
Lutrepulse
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 24, 2026, 1:03 AM EDT
Terminated No phase listed Observational

Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle

NCT00178542
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 24, 2026, 1:03 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis

NCT05862805
View directory record Official record
Conditions
Menstrual Bleeding, Heavy
Interventions
Sample Collection and Endometrial Biopsy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 24, 2026, 1:03 AM EDT
Not listed Not applicable Interventional

Baselines in Reproductive Disorders

NCT00456274
View directory record Official record
Conditions
Amenorrhea, Hypogonadotropic Hypogonadism, Kallmann's Syndrome
Interventions
Frequent baseline blood sampling
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

NCT02691494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 24, 2026, 1:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Quantifying Uterine Elastography in Menstruating Women

NCT06816381
View directory record Official record
Conditions
Infertility (IVF Patients), Infertility Assisted Reproductive Technology
Interventions
Shear wave elastography measurements
Device
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Placebo-Controlled Study to Evaluate the Effects of a Gummy and Capsule Supplement on Symptoms of Premenstrual Syndrome

NCT06763809
View directory record Official record
Conditions
PMS, Menstrual Cramp, Mood Change
Interventions
PMS Capsule, Capsule Placebo, PMS Gummy, Gummy Placebo
Dietary Supplement
Lead sponsor
Semaine Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 24, 2026, 1:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

NCT03704454
View directory record Official record
Conditions
Climacteric; Menorrhagia, Menopausal, Menopause
Interventions
50 mg PYC and then placebo, 100 mg PYC and then placebo, Placebo and then 50 mg PYC, Placebo and then 100 mg PYC
Dietary Supplement
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gresham, Oregon • Portland, Oregon • Tualatin, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 24, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease

NCT06064851
View directory record Official record
Conditions
Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
Interventions
Volta System
Device
Lead sponsor
Five Liters, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 24, 2026, 1:03 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

NCT06704594
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Interventions
sertraline 50 mg daily, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 24, 2026, 1:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Hydration & Female Life Stages

NCT07653620
View directory record Official record
Conditions
Dehydration, Menstruation, Pre-menopause, Peri-menopausal Women, Post-menopausal Women, Hydration
Interventions
placebo beverage, electrolyte beverage
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Bradenton, Florida • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 1:03 AM EDT